• Third Rock-backed Abata gets $95M to take cell therapy to MS, other autoimmune diseases

    1 month ago - By MedCity News

    Regulatory T cells, or Tregs, have shown promise as a treatment for autoimmune diseases. Abata Therapeutics has raised $95 million in Series A financing for its Treg technology and CEO Samantha Singer said that multiple sclerosis is the startup's first disease target.
    Read more ...